A phase II study of dasatinib in relapsed and-refractory chronic lymphocytic leukemia (CLL/SLL)

被引：6
|
作者：
Amrein, Philip C. [1 ]
Attar, Eyal C. [1 ]
Takvorian, Tak [1 ]
Hochberg, Ephraim P. [1 ]
Ballen, Karen [1 ]
Zabrieh, David [2 ]
Brown, Jennifer R. [2 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Dana Farber Canc Inst, Boston, MA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.3126.3126
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3126
引用
收藏
页码：920A / 920A
页数：1
相关论文
共 50 条
  • [1] Dasatinib Has Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL/SLL), a Phase II Trial
    Amrein, Philip C.
    Attar, Eyal
    Takvorian, Tak
    Hochberg, Ephraim
    Ballen, Karen K.
    Leahy, Kathleen M.
    Neuberg, Donna
    Brown, Jennifer R.
    BLOOD, 2008, 112 (11) : 1084 - 1084
  • [2] Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Amrein, Philip C.
    Attar, Eyal C.
    Takvorian, Tak
    Hochberg, Ephraim P.
    Ballen, Karen K.
    Leahy, Kathleen M.
    Fisher, David C.
    LaCasce, Ann S.
    Jacobsen, Eric D.
    Armand, Philippe
    Hasserjian, Robert P.
    Werner, Lillian
    Neuberg, Donna
    Brown, Jennifer R.
    CLINICAL CANCER RESEARCH, 2011, 17 (09) : 2977 - 2986
  • [3] Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Odetola, Oluwatobi
    Ma, Shuo
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2023, 18 (05) : 130 - 143
  • [4] Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Oluwatobi Odetola
    Shuo Ma
    Current Hematologic Malignancy Reports, 2023, 18 : 130 - 143
  • [5] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Van Den Neste, Eric
    Cazin, Bruno
    Janssens, Ann
    Gonzalez-Barca, Eva
    Jose Terol, Maria
    Levy, Vincent
    Perez de Oteyza, Jaime
    Zachee, Pierre
    Saunders, Andrew
    de Frias, Merce
    Campas, Clara
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 581 - 591
  • [6] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Eric Van Den Neste
    Bruno Cazin
    Ann Janssens
    Eva González-Barca
    María José Terol
    Vincent Levy
    Jaime Pérez de Oteyza
    Pierre Zachee
    Andrew Saunders
    Mercè de Frias
    Clara Campàs
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 581 - 591
  • [7] Results of a phase I trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).
    Woyach, Jennifer Ann
    Flynn, Joseph M.
    Jones, Jeffrey Alan
    Andritsos, Leslie A.
    Lucas, Margaret
    Chase, Weihong
    Yang, Ying
    Lucas, David M.
    Sass, Ellen
    Waymer, Sharon
    Ling, Yonghua
    Jiang, Yao
    Phelps, Mitch A.
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Phase I study of ofatumumab (OFA) in Japanese patients (JPN pts) with relapsed of refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
    Terui, Y.
    Ogura, M.
    Tobinai, K.
    Hatake, K.
    Suzuki, T.
    Muruyama, D.
    Miyazato, A.
    Katsura, K.
    Hotta, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Response to Dasatinib In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)-Correlates with p-Lyn and p-Syk
    Amrein, Philip C.
    Attar, Eyal C.
    Takvorian, Tak
    Hochberg, Ephraim
    Ballen, Karen K.
    Leahy, Kathleen M.
    Fisher, David C.
    LaCasce, Ann
    Jacobsen, Eric D.
    Armand, Philippe
    Hasserjian, Robert
    Werner, Lillian
    Neuberg, Donna
    Brown, Jennifer R.
    BLOOD, 2010, 116 (21) : 1020 - 1020
  • [10] A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL)
    Shouse, Geoffrey
    Chen, Lu
    Siddiqi, Tanya
    Muir, Alex
    Brown, Jennifer
    Spurgeon, Stephen
    Danilov, Alexey
    LEUKEMIA & LYMPHOMA, 2023, 64 : S105 - S106
12345